Juan Verdejo
Overview
Explore the profile of Juan Verdejo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Alvarez E, Verdejo J, Ocampo S, Ponte-Negretti C, Ruiz E, Rios M
Int J Cardiol Heart Vasc
. 2020 Sep;
29:100545.
PMID: 32885029
Background: In many patients, the risk of cardiovascular (CV) events persists despite statin treatment and attaining target LDL-c levels. This residual risk is in part attributed to atherogenic dyslipidemia (AD)....
2.
Gomez-Alvarez E, Verdejo J, Ocampo S, Ruiz E, Martinez-Rios M
Future Cardiol
. 2019 Dec;
16(1):53-60.
PMID: 31850802
To determine the effectiveness of Centro Nacional de Investigaciones Cardiovasculares (CNIC)-polypill (acetylsalicylic acid 100 mg, ramipril 5/10 mg, simvastatin 40 mg) in achieving blood pressure (BP) goals. A multicenter, observational,...
3.
Castellano J, Verdejo J, Ocampo S, Rios M, Gomez-Alvarez E, Borrayo G, et al.
Arch Med Res
. 2019 May;
50(1):31-40.
PMID: 31101241
Background: The cardiovascular disease pandemic has promoted the cardiovascular polypill as one of the most scalable public health strategies to improve cardiovascular risk by increasing accessibility and adherence to treatments....
4.
Gonzalez-Pacheco H, Amezcua-Guerra L, Vazquez-Rangel A, Martinez-Sanchez C, Perez-Mendez O, Verdejo J, et al.
Am J Cardiol
. 2015 Oct;
116(11):1651-7.
PMID: 26456205
Pathologic conditions associated with inflammation show an inverse correlation between high-density lipoprotein cholesterol (HDL-C) and inflammatory biomarker levels. Our aim was to investigate, in patients with acute coronary syndrome (ACS),...
5.
Jukema J, Chiang C, Ferrieres J, Santos R, Verdejo J, Waters D, et al.
Curr Med Res Opin
. 2010 Oct;
26(11):2589-97.
PMID: 20879831
Objective: This analysis of the Lipid Treatment Assessment Project 2 population compared lipid goal attainment by diabetes and metabolic syndrome status. Research Design And Methods: Dyslipidaemic patients aged ≥ 20...
6.
Santos R, Waters D, Tarasenko L, Messig M, Jukema J, Ferrieres J, et al.
Am Heart J
. 2009 Oct;
158(5):860-6.
PMID: 19853709
Background: Differences between women and men have been documented for both diagnostic testing and treatment in cardiology. This analysis evaluates whether low-density lipoprotein cholesterol (LDL-C) success rates according to current...
7.
Waters D, Brotons C, Chiang C, Ferrieres J, Foody J, Jukema J, et al.
Circulation
. 2009 Jun;
120(1):28-34.
PMID: 19546386
Background: Information about physicians' adherence to cholesterol management guidelines remains scant. The present survey updates our knowledge of lipid management worldwide. Methods And Results: Lipid levels were determined at enrollment...
8.
Rosas M, Pastelin G, Vargas-Alarcon G, Martinez-Reding J, Lomeli C, Mendoza-Gonzalez C, et al.
Arch Cardiol Mex
. 2008 Oct;
78 Suppl 2:S2-5-57.
PMID: 18928127
The multidisciplinary Institutional Committee of experts in Systemic Arterial Hypertension from the National Institute of Cardiology "Ignacio Chávez" presents its update (2008) of "Guidelines and Recommendations" for the early detection,...
9.
Velazquez Monroy O, Barinagarrementeria Aldatz F, Rubio Guerra A, Verdejo J, Mendez Bello M, Violante R, et al.
Arch Cardiol Mex
. 2007 May;
77(1):31-9.
PMID: 17500190
Cardiovascular diseases are the main cause of death and disability in México. 25% of deaths under 60 years of age are related to chronic degenerative diseases. These disorders are more...